Define molecular events driving selective neuronal death in multiple neurodegenerative diseases by snRNA-seq
Define molecular events driving selective neuronal death in multiple neurodegenerative diseases by snRNA-seq
批准号:
10323684
负责人:
Jinbin Xu
金额:
$15.75万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2021
资助国家:
美国
项目状态:
已结题
起止时间:
2021-01-15 至 2022-12-31
关键词:
AffectAgeAlzheimer&aposs DiseaseAlzheimer&aposs disease related dementiaAmericanArchivesAreaAttentionAutomobile DrivingBasal GangliaBiologicalBiological MarkersBiologyBrainCandidate Disease GeneCell NucleusCellsCharacteristicsClinicalCognitiveCollaborationsDataDementiaDevelopmentDiseaseDisease ProgressionEventFreezingFundingGene ExpressionHeterogeneityHippocampus (Brain)HumanImmunotherapyLaboratoriesLigandsMethodsMicrogliaMolecularNerve DegenerationNeurodegenerative DisordersNeurogliaNeuroimmuneNeuronsParkinson DiseaseParkinsonian DisordersPathologicPathologyPathway AnalysisPathway interactionsPatientsPopulationPredispositionPreventionProcessProteinsReceptor SignalingRegulationResearchResearch PersonnelResearch Project GrantsRoleSmall Nuclear RNASpecimenSubstantia nigra structureTechnologyTimeTissuesTremorUnited States National Institutes of Healthbrain tissuecell typecognitive functioncohortdisorder controldopaminergic neurongene regulatory networkgenome-wideimprovedinsightlongitudinal analysismacrophagemolecular markermotor learningmotor symptomneuroinflammationneuron lossnew therapeutic targetnext generationnovelpreventprogramssingle-cell RNA sequencingtooltranscriptometranscriptome sequencingtranscriptomicstreatment strategy
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Project Summary
Despite decades of research, currently the mechanisms of neurodegeneration in Alzheimer’s
disease (AD) and Parkinson Disease (PD) remain controversial and there are no therapies can
prevent, slow, or halt disease progression. Neurodegenerative diseases have two fundamental
general characteristics. 1) The pathology associated with the disease only affects particular
neurons (‘selective neuronal vulnerability’); 2) The pathology worsens with time and impacts more
regions in a stereotypical and predictable fashion. The discovery of key pathways that regulate
this differential susceptibility of neurons to degeneration holds great potential for the discovery of
novel drug targets and the development of promising neuroprotective treatment strategies.
However, the mechanisms underlying selective neuronal and regional vulnerability have been
difficult to dissect because of our limited ability to distinguish different neuronal subpopulations.
Loss of dopaminergic neurons in the SN is a hallmark of PD which underlies the parkinsonian
motor symptoms such as rigidity and tremor. Neuronal loss also occurs in the SN of AD [8, 9],
however, often without co-occurring parkinsonian motor symptoms. Dopaminergic neurons within
the SN are highly heterogeneous [10] and the loss of the dopaminergic neurons in PD is
heterogeneous across different axes [11-14]. It is unclear whether the same population of neurons
were lost in AD and PD and whether the mechanisms of neuronal loss are shared between the
two diseases. Neuroinflammation - activation of the neuroimmune cells (e.g. microglia) into
proinflammatory states - are shared pathological contributors in AD and PD. However, the
molecular identity of different microglia subpopulations and the role of neuroinflammation in the
selective neuronal death remain unclear. Therefore, we propose to use single nucleus RNA-seq
(snRNA-seq), an unbiased approach to identify and characterize distinct cell populations in
tissues, to dissect the mechanisms underlying selective neuronal death. Specifically, our specific
aims are: Aim 1: Characterize and validate cellular heterogeneity, cellular and
transcriptomic changes of neuron and microglia from the SN brain tissues of AD, PD
patients and age-matched controls. Aim 2: Dissect the mechanisms of cell composition
and transcriptome dysregulation in AD and PD. Our study will provide 1) molecular markers
and tools for targeted neuronal and microglia subpopulation isolation and manipulation; 2) better
understanding of the dynamic change of different neuronal and microglia subpopulation, their
transcriptomic changes and the putative regulatory mechanisms in AD and PD; 3) high-
confidence new candidate genes and pathways as targets to develop effective immunotherapies
or neuroprotective strategies.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Optimization of imaging mass cytometry, a single-cell spatial proteomics technology, for the study of Alzheimer disease
-
批准号:10447479
-
项目类别:
-
资助金额:$43.31万
-
财政年份:2022
-
负责人:Jinbin Xu
-
依托单位:
Dissect the mechanisms of selective regional vulnerability in Lewy Body Dementias via comparative snRNA-seq analysis
-
批准号:10292776
-
项目类别:
-
资助金额:$71.01万
-
财政年份:2021
-
负责人:Jinbin Xu
-
依托单位:
Dissect the mechanisms of selective regional vulnerability in Lewy Body Dementias via comparative snRNA-seq analysis
-
批准号:10449397
-
项目类别:
-
资助金额:$69.81万
-
财政年份:2021
-
负责人:Jinbin Xu
-
依托单位:
Dissect the mechanisms of selective regional vulnerability in Lewy Body Dementias via comparative snRNA-seq analysis
-
批准号:10685608
-
项目类别:
-
资助金额:$72.01万
-
财政年份:2021
-
负责人:Jinbin Xu
-
依托单位:
POSTMORTEM VALIDATION OF BIOMARKERS FOR IMAGING PARKINSON DISEASE
-
批准号:9210662
-
项目类别:
-
资助金额:$33.36万
-
财政年份:2016
-
负责人:Jinbin Xu
-
依托单位:
POSTMORTEM VALIDATION OF BIOMARKERS FOR IMAGING PARKINSON DISEASE
-
批准号:9105072
-
项目类别:
-
资助金额:$33.36万
-
财政年份:2016
-
负责人:Jinbin Xu
-
依托单位:
DOPAMINE D1, D2, AND D3 RECEPTORS AS BIOMARKERS FOR IMAGING NIGROSTRIATAL NEURONS
-
批准号:8807974
-
项目类别:
-
资助金额:$7.63万
-
财政年份:2014
-
负责人:Jinbin Xu
-
依托单位:
DOPAMINE D1, D2, AND D3 RECEPTORS AS BIOMARKERS FOR IMAGING NIGROSTRIATAL NEURONS
-
批准号:8918756
-
项目类别:
-
资助金额:$7.63万
-
财政年份:2014
-
负责人:Jinbin Xu
-
依托单位:
国内基金
海外基金
登录
查看更多内容
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
-
批准号:JCZRLH202601523
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
-
批准号:JCZRQN202500010
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:
-
依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
-
批准号:2025JJ70209
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:雷芬芳
-
依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
-
批准号:--
-
项目类别:面上项目
-
资助金额:--
-
批准年份:2024
-
负责人:万荣
-
依托单位:
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
-
批准号:2023JJ50274
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2023
-
负责人:贺志明
-
依托单位:
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
-
批准号:--
-
项目类别:地区科学基金项目
-
资助金额:33万元
-
批准年份:2022
-
负责人:都义日
-
依托单位:
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:叶宝东
-
依托单位:
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2022
-
负责人:于海兵
-
依托单位:
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
-
批准号:81973577
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2019
-
负责人:辛贵忠
-
依托单位:
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
-
批准号:81602908
-
项目类别:青年科学基金项目
-
资助金额:18.0万元
-
批准年份:2016
-
负责人:刘括
-
依托单位: